Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Biotech company Cryosite (CTE) has appointed John Hogg as its new company CEO
  • John has been with the company since July 2018 and was promoted to General Manager of Operations in December 2019
  • He will begin his new role on Monday (October 19)
  • Bryan Dulhunty will step down from his current role as Executive Chairman to non-Executive Chairman
  • On market close, Cryosite is down 5.88 per cent and is trading for 24 cents per share

Biotech company Cryosite (CTE) has appointed John Hogg as CEO as its new company CEO.

John has been with the company since July 2018 and was promoted to General Manager of Operations on December 1, 2019.

He is highly experienced in warehousing, logistics and supply chain management. Previously, John was an independent consultant, contractor and a functional manager for Allergan, Boots International Healthcare, Johnson & Johnson, Philips Electronics, and UTI Worldwide international freight forwarders.

“He has deployed his skills and experience in Australia, Asia and the U.S. John has qualifications in materials management, freight management, accounting and computing, including European Senior Logistician certification and he is a Chartered Member of The Chartered Institute of Logistics and Transport,” the company told the market.

John will begin his new role on Monday (October 19). Bryan Dulhunty will step down from his current role of Executive Chairman to non-executive Chairman.

Bryan was appointed Chairman in March 2018 and then took on the role as Executive Chairman in June 2019. His role was to drive change in the company, the first stage of this change has now been complete.

The future operational development and growth of Cryosite will now be driven by John.

On market close, Cryosite is down 5.88 per cent and is trading for 24 cents per share.

CTE by the numbers
More From The Market Herald

" Recce Pharmaceuticals (ASX:RCE) receives positive safety data from second cohort of Phase I Clinical Trial

Recce Pharmaceuticals (ASX:RCE) has released positive safety data from its second cohort of subjects for its…
Virtus Health (ASX:VRT) - CEO & Managing Director, Kate Munnings

" Virtus Health (ASX:VRT) has non-urgent elective surgeries suspended in NSW & VIC

Virtus Health (ASX:VRT) has had its non-urgent elective surgeries suspended in NSW and Victoria as the…

" Creso Pharma (ASX:CPH) appoints William Lay as CEO & MD

Creso Pharma (ASX:CPH) has strengthened its board with the appointment of William Lay as CEO and…

" Monash IVF Group (ASX:MVF) suspends certain procedures in Victoria

Following new health orders in Victoria, Monash IVF Group (ASX:MVF) says non-urgent surgery protocols will disrupt…